Hanmi Pharmaceutical is also developing a treatment ... of this year and apply for product approval from the Ministry of Food and Drug Safety in the second half. Choi said, "Efeglenantide is ...

Volpi Foods, a leader in authentic, craft-cured meats, is proud to announce the renewal and expansion of its partnership with ...

South Korea's position in the global representative stock index Morgan Stanley Capital International (MSCI) Emerging Markets ...

Wall Street has remained volatile since the beginning of this year, with multiple factors denting investors’ sentiment. An unexpected surge in inflation, uncertainty over the Federal Reserve’s future ...

Net income: US$62.2m (down 22% from FY 2023). Profit margin: 27% (down from 32% in FY 2023). The decrease in margin was ...

Projected low-to-mid single-digit loan growth in 2025. Hanmi Financial demonstrated solid performance in 2024, reporting a net income of $62.2 million, or $2.05 per diluted share. The company ...

Ben Brodkowitz; Investor Relations; Financial Profiles, Inc. Bonita Lee; President, Chief Executive Officer, Director; Hanmi Financial Corp Anthony Kim; Senior Executive Vice President ...

LOS ANGELES, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Hanmi Financial Corporation (NASDAQ: HAFC, or “Hanmi”), the parent company of Hanmi Bank (the “Bank”), today announced that its Board of ...

Theratechnologies Inc. ("Theratechnologies" or the "Company") , a specialty biopharmaceutical company focused on the commercialization of innovative therapies that have the potential to redefine ...

SAN FRANCISCO ― Hanmi Pharmaceutical is poised to bring a new chapter to obesity treatment, a topic that has garnered significant attention at this year’s JP Morgan Healthcare Conference.

LOS ANGELES (AP) — LOS ANGELES (AP) — Hanmi Financial Corp. (HAFC) on Tuesday reported fourth-quarter profit of $17.7 million. The bank, based in Los Angeles, said it had earnings of 58 cents per ...